Over the years, we have systematically leveraged our technology platforms from enzymes to small molecules
to recombinant proteins and antibodies. Through partnerships and alliances, Biocon has strategically moved up the value chain from supplying pharmaceutical bulk actives to developing proprietary molecules and our own branded formulations.

In the areas of custom and clinical research services, collaborative partnerships with complementary biotechnology and pharmaceutical companies are yielding rich results. We believe these partnerships will positively impact any and all phases of our discovery portfolio.

Differentiation and a high degree of innovation distinguish all our products and services. Combined with India’s value advantage, they enable us to develop and deliver novel and affordable therapeutics for global unmet medical needs.